By vgreene, 4 March, 2021 Multicenter multinational double blind RCT 438 hospitalized pts mean age 60y w severe dz received TCZ 8 mg kg IV x1 max 800 mg dose n 294 or placebo n 144 25 pts received 2nd TCZ dose 8 24h after 1st dose SOC included antiviral tx low dose CS convalescent
By vgreene, 4 March, 2021 Study considerations lack of standardized tx across sites countries lower percentage of TCZ group received CS possible selection bias since pts w 2nd TCZ dose had worse outcomes dose relative to sx onset not evaluated
By vgreene, 4 March, 2021 KEY FINDINGS TCZ didn t improve clinical status or mortality at 28 days vs placebo
By vgreene, 4 March, 2021 Tocilizumab in Hospitalized Patients With Severe Covid 19 Pneumonia COVACTA
By vgreene, 4 March, 2021 Median organ support free days TCZ 10 vs sarilumab 11 vs control group 0 adjusted OR 1 64 for TCZ 1 76 for sarilumab 90 day survival analysis improved survival in pooled IL 6 antagonist group vs control group HR 1 61 95 credible interval 1 25 to 2 08
By vgreene, 4 March, 2021 Multinational adaptive platform trial critically ill pts mean age 61 4y w severe dz and w in 24h of cardiopulmonary support received TCZ 8 mg kg IV x1 max 800 mg dose n 353 sarilumab 400 mg IV x1 n 48 or SOC n 402 w in 24h of ICU admission 29 pts received
By vgreene, 4 March, 2021 Study considerations open label pragmatic design preliminary report complex statistical model
By vgreene, 4 March, 2021 KEY FINDINGS TCZ and sarilumab improved outcomes incl survival in critically ill pts w COVID 19 on organ support
By vgreene, 4 March, 2021 Interleukin 6 Receptor Antagonists in Critically Ill Patients With Covid 19 REMAP CAP
